Angela Platt‐Higgins

University of Liverpool — United Kingdom

Biochemistry, Genetics and Molecular Biology · Life Sciences

26h-index2.6kcitations91works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

S100 Proteins and Annexins(20), Cell death mechanisms and regulation(18), Cancer-related Molecular Pathways(14), Brain Metastases and Treatment(11), Nuclear Structure and Function(10)

Publications91 total

Corrigendum to “Development and validation of Ran as a prognostic marker in stage I and stage II primary breast cancer” [Life Sci., 329 (2023) 121964]
Life Sciences·2023· 1 cited
Development and validation of Ran as a prognostic marker in stage I and stage II primary breast cancer
Life Sciences·2023· 8 cited
Targeted Destruction of S100A4 Inhibits Metastasis of Triple Negative Breast Cancer Cells
Biomolecules·2023· 15 citedOpen Access
Supplementary Figure 10 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
2023Open Access
Supplementary Figure 8 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
2023Open Access
Supplementary Figure 4 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
2023Open Access
Supplementary Figure 1 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
2023Open Access
Supplementary materials and methods from S100A4 Elevation Empowers Expression of Metastasis Effector Molecules in Human Breast Cancer
2023Open Access
Supplementary Tables 1-3 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
2023Open Access
Supplementary Figure 9 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
2023Open Access
Supplementary Figure Legends 1-10 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
2023Open Access
Supplementary Figure 5 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
2023Open Access
Suplementary Figures from S100A4 Elevation Empowers Expression of Metastasis Effector Molecules in Human Breast Cancer
2023Open Access
Supplementary Figure 8 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
2023Open Access
Supplementary Methods and Materials from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
2023Open Access
Supplementary Figure 10 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
2023Open Access
Supplementary methods from T-Cell Densities in Brain Metastases Are Associated with Patient Survival Times and Diffusion Tensor MRI Changes
2023Open Access
Data from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
2023Open Access
Supplementary Tables from S100A4 Elevation Empowers Expression of Metastasis Effector Molecules in Human Breast Cancer
2023Open Access
Supplementary Figure 5 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Philip S. Rudland(47), Roger Barraclough(21), Mohamed El‐Tanani(14), John Winstanley(12), Suzete de Silva Rudland(9), Rasheed Zakaria(7), Michael D. Jenkinson(7), Patrick G. Johnston(7), Christopher R. West(6), Hiu‐Fung Yuen(6), Kenneth J. O’Byrne(6), Shudong Zhang(5), Athina Giannoudis(5), Carlo Palmieri(5), Claire Grills(5), James T. Murray(5), Osama Sharaf Eldin(5), Pasi A. Jänne(5), Dean A. Fennell(5), Dong L. Barraclough(4)